Moderna, Inc. Profile Avatar - Palmy Investing

Moderna, Inc.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the Uni…
Biotechnology
US, Cambridge [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 28% Weak
Profitability n.A. n.A.
Fin. Growth 67% Positive
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA -73.40 -32.12 120.75
Graham Fair Price 123.23 48.19 21.59
PEG -96.75 0.01 -0.41
Price/Book 15.08 3.15 2.73
Price/Cash Flow -63.88 -34.04 94.25
Prices/Earnings -80.34 -8.58 43.65
Price/Sales 1693.29 241.55 13.47
Price/FCF -63.88 -34.04 94.25
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin -68.71 0.21 0.67
Operating Margin 355314.97 -7.58 < 0.005
ROA 496.40 -0.07 0.01
ROE 0.02 -0.09 485.28
ROIC < 0.005 -0.09 7274.34
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ < 0.005 -0.02 78.83
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 1.00 -212.00 21036.97
EPS QOQ 1.06 -6.40 504.21
FCF QOQ 1.23 -3.95 220.69
Revenue QOQ 0.54 -0.94 75.39
Naive Interpretation member
03 - Financial Growth · Positive
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 19.57 201.14 927.81
Days Sales Outstanding (DSO) 34.59 208.56 503.03
Inventory Turnover 4.60 0.45 -90.27
Debt/Capitalization 0.08 0.09 6.90
Quick Ratio 3.21 3.75 16.77
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 36.36 33.55 -7.73
Cash 22.58 22.36 -1.00
Capex -0.58 -0.51 11.14
Free Cash Flow 1.06 -3.10 194.00
Revenue 7.38 0.44 -94.08
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 3.42 4.03 17.79
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -5.55 0.68 -87.82
Naive Interpretation Member
06 - Financial Health · Bad
End of MRNA's Analysis
CIK: 1682852 CUSIP: 60770K107 ISIN: US60770K1079 LEI: - UEI: -
Secondary Listings